The development of novel treatment of age-related macular degeneration using high-density lipoprotein

2016 Fiscal Year Final Research Report

• Project/Area Number: 16H06909
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Ophthalmology
• Research Institution: Kyoto University
• Principal Investigator: Suda Kenji 京都大学, 医学研究科, 医員 (70779157)
• Research Collaborator: MURAKAMI Tatsuya 富山県立大学, 工学部医薬品工学科, 教授
• Project Period (FY): 2016-08-26 – 2017-03-31
• Keywords: 点眼ドラッグデリバリーシステム / 高比重リポタンパク / 加齢黄斑変性

Outline of Final Research Achievements

We have developed the novel drug delivery system using mutated forms of recombinant high-density lipoprotein (HDL), which is famous for anti-atherogenic property. For the achievement of less-invasive therapy of age-related macular degeneration, we searched for anti-angiogenetic drug that can be encapsulated into recombinant HDL. As a result, we succeeded in preparation of a recombinant HDL mutant loaded with pazopanib hydrochloride. We also confirmed the therapeutic potential of the complex in laser-induced choroidal neovascularization model mice.

Free Research Field

眼科